|本期目录/Table of Contents|

[1]毛婷,毛玲,管晓翔.PD-1/PD-L1免疫检查点抑制剂治疗三阴性乳腺癌的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(05):511-515.[doi:10.3969/j.issn.1672-271X.2021.05.014]
　MAO Ting,MAO Ling,GUAN Xiao-xiang.Research progress of PD-1 / PD-L1 immune checkpoint inhibitors in the treatment of triple negative breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(05):511-515.[doi:10.3969/j.issn.1672-271X.2021.05.014]
点击复制

PD-1/PD-L1免疫检查点抑制剂治疗三阴性乳腺癌的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年05
页码:
511-515
栏目:
综述
出版日期:
2021-09-20

文章信息/Info

Title:
Research progress of PD-1 / PD-L1 immune checkpoint inhibitors in the treatment of triple negative breast cancer
作者:
毛婷; 毛玲; 管晓翔
作者单位：214000无锡，解放军联勤保障部队第九○四医院消化内科（毛婷）；210029 南京，南京医科大学第一附属医院肿瘤科（毛玲、管晓翔）
Author(s):
MAO Ting1;  MAO Ling2 ;  GUAN Xiao-xiang2
（1.Department of Gastroenterology, The 904th Hospital of The Chinese People’s Liberation Army, Wuxi 214000, Jiangsu, China; 2. Department of Medical Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China)
关键词:
三阴性乳腺癌; 程序性细胞死亡蛋白1; 程序性细胞死亡蛋白配体1; 免疫疗法
Keywords:
triple-negative breast cancer;  programmed cell death protein 1;  programmed cell death protein ligand-1;  immunotherapy
分类号:
R737.9
DOI:
10.3969/j.issn.1672-271X.2021.05.014
文献标志码:
A
摘要:
三阴性乳腺癌（TNBC）是一种具有特殊生物学行为及临床病理特征的乳腺癌亚型。具有高度的肿瘤异质性，进展迅速、侵袭转移能力强、预后差，死亡率高等特点。遗传多样性及药物耐受性差，内分泌及抗Her-2治疗均无效，目前临床尚缺乏特效治疗手段，亦是临床诊疗上的难点。肿瘤免疫疗法是采用各种手段激活身体内的抗肿瘤免疫反应，最后杀死、清除肿瘤细胞的治疗方法。以程序性细胞死亡蛋白1（PD-1）/程序性细胞死亡蛋白配体1（PD-L1）为代表的免疫检查点抑制剂为TNBC治疗提供新的方案。PD-1/PD-L1信号通路可通过多种方式介导肿瘤免疫逃逸，阻断该通路成为目前肿瘤治疗的热点。抗PD-1/PD-L1单克隆抗体的临床疗效为TNBC治疗带来新的突破。文章主要就PD-1/PD-L1信号通路的作用机制、PD-1/PD-L1抑制剂的临床应用及相关研究进行综述。
Abstract:
Triple negative breast cancer (TNBC) is a subtype of breast cancer with special biological behavior and clinicopathological characteristics. TNBC is characterized by high heterogeneity, rapid progression, strong invasion and metastasis, poor prognosis and high mortality. The genetic diversity and drug tolerance of TNBC are poor. Endocrine and anti-Her-2 therapy are ineffective. At present, there is a lack of effective treatment, which is the difficulty of clinical treatment. Tumor immunotherapy is a kind of therapy which activates the body’s anti-tumor immune response, and finally kills tumor cells. The immune checkpoint inhibitors represented by programmed cell death protein-1 (PD-1) / programmed cell death protein ligand-1 (PD-L1) provide a new scheme for the treatment of TNBC. PD-1 / PD-L1 signaling pathway can mediate tumor immune escape in a variety of ways. Blocking this pathway has become a hot spot in cancer therapy. The clinical efficacy of anti-PD-1 / PD-L1 monoclonal antibody brings a new breakthrough for the treatment of TNBC. This paper reviews the mechanism of PD-1 / PD-L1 signaling pathway, the clinical application and related research of PD-1 / PD-L1 inhibitors.

参考文献/References:

[1]Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneousdisease[J]. Nat Rev Clin Oncol, 2016,13(11):674-690.
[2]Rigiracciolo DC, Nohata N, Lappano R, et al. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells[J]. Cells, 2020,9(4):1010.
[3]Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network[J]. Cancer, 2012, 118(22): 5463-5472.
[4]Fosu-Mensah N, Peris MS, Weeks HP, et al. Advances in small-molecule drug discovery for triple-negative breast cancer[J]. Future Med Chem, 2015,7(15):2019-2039.
[5]Hwang S, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breastcancer[J]. Pharmacol Ther, 2019, 199:30-57.
[6]Lotfinejad P, Kazemi T, Mokhtarzadeh A, et al. PD-1/PD-L1 axis importance and tumor microenvironment immune cells[J]. Life Sci, 2020, 259:118297.
[7]Hollern DP, Xu N, Thennavan A, et al. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer[J]. Cell,2019,179(5):1191-1206.
[8]Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies incancer： mechanisms of action, efficacy,and limitations[J]. Front Oncol,2018,8:86.
[9]Asano Y, Kashiwagi S, Goto W, et al. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression[J]. J Transl Med,2018,16(1):87.
[10]Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer(TNBC):where to go from here[J]. Cancer-Am Cancer Soc,2018,124(10):2086-2103.
[11]Qin G, Wang X, Ye S, et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer[J]. Nat Commun, 2020,11(1):1669.
[12]Wang Y, Wang H, Yao H, et al.Regulation of PD-L1: emerging routes for targeting tumor immuneevasion[J]. Front Pharmacol, 2018,9:536.
[13]Mazza C, Escudier B, Albiges L. Nivolumab in renal cell carcinoma: latest evidence and clinicalpotential[J]. Ther Adv Med Oncol,2017,9(3):171-181.
[14]Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial[J]. Nat Med,2019,25(6):920-928.
[15]Kleef R, Moss R, Szasz AM, et al. Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2[J]. Integr Cancer Ther, 2018,17(4):1297-1303.
[16]Cortes J, Cescon DW, Rugo HS, et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020,396(10265):1817-1828.
[17]Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breastcancer[J]. Cancer Immunol Immunother, 2021,70(3):607-617.
[18]Amens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breastcancer[J]. JAMA Oncol,2019,5(1):74.
[19]Mohan N, Hosain S, Zhao J, et al. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+triple negative breast cancer cells[J]. Oncoimmunology,2019,8(9):e1624128.
[20]Loibl S, Untch M, Burchardi N, et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in earlytriple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol,2019, 30(8):1279-1288.
[21]Tarantino P, Gandini S, Trapani D, et al.Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinicaltrials[J]. Crit Rev Oncol Hematol, 2021,159:103223.
[22]Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study[J]. Breast Cancer Res Treat,2018,167(3): 671-686.
[23]Kadono T. Immune-related adverse events by immune checkpointinhibitors[J]. Nihon Rinsho Meneki Gakkai Kaishi,2017,40(2):83-89.
[24]Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers,2020,6(1):38.
[25]Geisler AN, Phillips GS, Barrios DM,et al. Immune checkpoint inhibitor-related dermatologic adverse events[J]. J Am Acad Dermatol,2020,83(5):1255-1268.
[26]Bukamur H, Katz H, Alsharedi M, et al. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab[J]. South Med J,2020,113(11):600-605.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-10-11